Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

NCT02942706 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: mFOLFOX6
DRUG: FOLFIRI

Sponsor

Ruijin Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]